Transforming cancer care in Africa
Cancer Research and Clinical Trials
At NSIA-LUTH Cancer Centre (NLCC), we are not only committed to providing the best care for our patients but also to advancing the knowledge and practice of oncology in Nigeria and beyond. We conduct cutting-edge research and clinical trials to improve the prevention, diagnosis, and treatment of cancer.
Cancer Research
NLCC prides itself as a cancer research institution with one of the most accurate and insightful cancer databases in Nigeria. We collect and analyze data from our patients and other sources to generate evidence-based insights that inform our clinical practice and policy recommendations. We also collaborate with local and international partners to conduct multidisciplinary research projects that address the challenges and opportunities in the field of oncology.
Our reputation as a leading oncology research institution in Africa is underpinned by our significant achievements. We have received four research grants from various international organizations, and we currently have over 15 research projects in progress. Our dedication to advancing knowledge in oncology is reflected in the numerous publications we’ve produced since our inception in 2019.
Clinical Trials
NLCC is also a go-to institution for clinical trials and research and study partnerships. We work with clinical study teams, pharmaceutical and biomedical organizations, and academic institutions to conduct high-quality and ethical clinical trials that aim to improve the outcomes and quality of life of cancer patients.
Some of the clinical trials currently ongoing at the centre include:
HYPO Africa Trial: NLCC is one of the two participating institutions in the HYPOAfrica trial, which aims to prove the efficiency of the use of Hypofractionated Radiotherapy for Prostate cancer in men. This trial is sponsored by the International Atomic Energy Agency (IAEA) and the European Society for Radiotherapy and Oncology (ESTRO).
ARETTA HER2 - Positive Breast Cancer Study: The centre is one of the participating centres in the trial ARETTA (Assessing Response to neoadjuvant Taxotere and TrAstuzumab) in Nigerian women with HER2-positive breast cancer. This study is done with support from Roche Pharmaceuticals, University of Chicago, and other partners.
We are committed to pushing the boundaries of cancer research and providing patients with the most advanced and effective treatments. Our dedication to excellence is evident in our ongoing trials, publications, and contributions to the field of oncology.
For more information about our cancer research and clinical trials, please contact us directly at research@nlcc.ng to learn more about our research initiatives and how you can get involved. Join us in our mission to make a difference in the fight against cancer.
References
Patient's Perspective on the Impact of COVID-19 on Cancer Treatment in Nigeria in the JCO Global Oncology Journal (American Society of Clinical Oncology). https://ascopubs.org/doi/full/10.1200/GO.21.00244
Challenges and Opportunities for Increasing Adoption of Hypofractionated Radiotherapy in Low- and Middle-Income Countries in the Astro International Journal of Radiation Oncology, Biology and Physics. https://www.redjournal.org/article/S0360-3016(22)02137-X/fulltext
Evaluation of IMRT and Double-Arc VMAT treatment plans in Head and Neck Cancer Cases: Our Experience at NSIA-LUTH Cancer Care published in the African Journal of Medical Physics (AJMP). https://globalmedicalphysics.org/wp-content/uploads/2020/11/AJMP-31-1-5-Final.pdf
The path to becoming a clinical or radiation oncologist in Nigeria in the ecancer medical science journal. https://ecancer.org/es/journal/article/1440-the-path-to-becoming-a-clinical-or-radiation-oncologist-in-nigeria
Oncology Education in the Nigerian Medical Curriculum: A cross-sectional review in the Nigerian Medical Journal. https://www.nigerianmedjournal.org/index.php/nmj/article/view/22
Challenges and opportunities for implementing hypofractionated radiotherapy in Africa: lessons from the HypoAfrica clinical trial in the ecancer medical science journal. https://ecancer.org/en/journal/article/1508-challenges-and-opportunities-for-implementing-hypofractionated-radiotherapy-in-africa-lessons-from-the-hypoafrica-clinical-trial
Evaluation of Three-Dimensional Conformal Radiotherapy and Intensity Modulated Radiotherapy Techniques for Left Breast Post-Mastectomy Patients: Our Experience in Nigerian Sovereign Investment Authority-Lagos University Teaching Hospital Cancer Center, South-West Nigeria in the European Journal of Breast Health. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246049/
Breast Cancer Radiotherapy Experience in a Newly Established Cancer Center in Nigeria in the Astro International Journal of Radiation Oncology, Physics and Biology. https://www.redjournal.org/article/S0360-3016(22)02134-4/fulltext
Dosimetric Evaluation of Intensity Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy Treatment Plans for Prostate Cancer in the Turkish Journal of Oncology. https://onkoloji.dergisi.org/pdf/pdf_TOD_1191.pdf
Examining Cancer Patients' Perceptions of the Impact of COVID-19 on Teleoncology: Findings From 15 Nigerian Outpatient Cancer Clinics in the JCO Global Oncology. https://ascopubs.org/doi/full/10.1200/GO.22.00221
Direct cost of treating childhood cancer in Lagos, Nigeria: A tale of financial inaccessibility to care in the Journal of Clinical Sciences. https://jcsjournal.org/article.asp?issn=2468-6859;year=2021;volume=18;issue=4;spage=179;epage=185;aulast=Joseph
Early Detection of Paediatric Cancer: Equipping Primary Health‑Care Workers in Nigeria in the Nigerian Journal of Medicine. https://www.ajol.info/index.php/njm/article/view/224344
Clinical and non-clinical determinants of cervical cancer mortality: A retrospective cohort study in Lagos, Nigeria in the Frontiers In Oncology Journal (National Library of Medicine). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978796/pdf/fonc-13-1105649.pdf